The observation made by Seccherio and colleagues (2007) that MDM2 antagonist Nutlin-3 inhibits cell cycle progression and cell migration in HUVEC was one of the first lines of evidence that MDM2 could facilitate the activation of endothelial cells to support tumor angiogenesis. The gene discussed is MDM2; the disease is neoplasm.